Abstract
It has been widely accepted that the secretion of prolactin (PRL) is controlled mainly by the tonic inhibition of the hypothalamus via PRL release inhibiting factor (PIF), and dopamine seems to be the most important PIF (Macleod and Lehmeyer, 1974; Takahara et al.; 1974) . On the other hand, there are such substances in the brain as serotonin (Iwasaki et al., 1978; Kamberi et al., 1971) , histamine (Donoso et al., 1976; Libertun et al., 1976) , TRH (Bower et al., 1971; Tashijian et al., 1971) and VIP (Kato et al., 1978b; Ruberg et al., 1978) that seems to play a stimulatory role in PRL release. Recently, morphinomimetic peptides have been isolated from the mammalian central nervous system (Cox et al., 1976; Hughes et al., 1975 ) and subsequently they have been proved to stimulate PRL secretion (Bruni et al., 1977; Dupont et al., 1977; Ferland et al., 1977; Kato et al., 1978a; Rivier et al., 1977a) . However, the interaction of these opioid peptides with brain amines and other neuropeptides has not been fully elucidated. In the present experiments, we studied the relationship between brain amines and opioid peptides in regulating PRL secretion using a synthetic analogue of Met5-enkephalin, [D-Ala2, MePhe4, Met(o)5-ol] enkephalin, which has a long-lasting analgesic action and a potent stimulating effect on PRL secretion (Kato et al., 1980; Roemer et al., 1977; von Graffenried et al., 1978) .
Materials and Methods

Animals
Wistar strain male rats weighing 200-220g (Japan Animal Co., Osaka) were maintained in a temperature et al. 10-6 M) caused a rapid and remarkable increase in PRL in the effluent. (Fig. 7) .
Discussion
The present study clearly demonstrated that intravenous injection of FK 33-824 causes a dose-related rise in plasma PRL levels, and the response is blocked by naloxone, a specific opiate antagonist. These findings support Opiate receptors are known to exist in the hypothalamus and in the pituitary (Kuhar et al., 1973; Simantov and Snyder, 1977) . Lien et al. (1976) have reported that Leu5-enkephalin increased PRL release from rat pituitary cell cultures, suggesting a direct action of the opioid peptide on the pituitary. Enjalbert et al. (1979) noted that endorphins blocked dopamine inhibition of RPL secretion in vitro. In contrast, subsequent studies have shown that endorphins do not stimulate PRL secretion from the pituitary in vitro Rivier et al., 1977a; Shaar et al., 1978) . In our study, FK 33-824 had no stimulatory effect on PRL secretion by rat anterior pituitary cells in vitro, and it did not attenuate the suppressive effect of dopamine.
Our results suggest the involvement of the central nervous system in the action of FK 33-824. However, the possible direct action of other endogenous opioid peptides cannot be completely ruled out when the results of the present study are considered. pituitary gland. Dopaminergic mediation of the endorphin-induced RPL release has been also suggested by several investigators using the dopamine receptor blocker (Dupont et al., 1979; van Vugt et al., 1979) . A decrease in the turnover of dopamine in the hypothalamus (Deyo et al., 1979; Ferland et al., 1977; van Loon et al., 1980) and a reduction in the dopamine concentration in the hypophysial portal blood induced by opioid peptides (Gudelsky et al., 1979) It has been reported that opioid peptides increase brain serotonin turnover (Algeri et al., 1978; van Loon et al., 1978) . Spampinato et al. (1979) have recently demonstrated that treatment with 5,6-DHT, a drug neurotoxic to serotonergic nerve, almost completely abolished the rise in plasma PRL induced by the opioid peptide. Koenig et al. (1980) have reported that morphine-induced PRL release is inhibited by 5,7-DHT treatment. These results suggest serotonergic involvement in the PRL release induced by the opioid peptide.
However, Spampinato et al. (1979) and Tache et al. (1979) failed to demonstrate the reduction in PRL response to morphine and opioid peptides following treatment with PCPA, an inhibitor of serotonin biosynthesis. In the present study, the PRL response to FK 33-824 was not impaired by 5,6-DHT treatment, which is known to degenerate the central serotonergic system (Bjorklund et al., 1974 Intraventricular injection of histamine causes a dose-dependent rise in PRL secretion and the response is blocked by diphenhydramine, a histamine H1-receptor blocker, in the rat (Donoso et al., 1979; Libertun et al., 1976) . Since both diphenhydramine and naloxone suppress PRL release induced by morphine (Rivier et al., 1977b) , we investigated the potential role of histamine in FK 33-824-induced PRL release in the rat. However, the lack of any modification by DPH in the PRL response to FK 33-824 suggests that the effect of FK 33-824 on PRL secretion is not mediated through histaminergic pathways. These results seem to indicate that the morphine and FK 33-824 action modes are different. Further studies are required to elucidate the role of histamine in PRL secretion induced by the endogenous opioid peptide.
